Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

While InvestingPro data ... sequencing continues to decrease, more researchers and clinicians may be able to incorporate genomic analysis into their work, expanding the overall market for Illumina ...

being held in Florida—where the DNA sequencing giant is set to unveil more details and demonstrations—and follows up on Illumina’s recent expansions into proteomics and single-cell analysis.

At AGBT, customers will present data demonstrating unparalleled ... at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology ...

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...

According to InvestingPro data ... As the cost of sequencing continues to decrease, more researchers and clinicians may be able to incorporate genomic analysis into their work, expanding the overall ...